BMaP-3 Cancer Database. Aggregate Data File

Similar documents
December 2002 Monthly Memo

Rare Breast Tumours. 1. Breast Tumours. 1.1 General Results. 1.2 Incidence

Basement membrane in lobule.

Recent advances in breast cancers

Contents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ

Collecting Cancer Data: Breast. Prizes! Collecting Cancer Data: Breast 8/4/ NAACCR Webinar Series 1. NAACCR Webinar Series

CURRICULUM FOR THE BREAST PATHOLOGY ROTATION UNIVERSITY OF FLORIDA DEPARTMENT OF PATHOLOGY

2007 Multiple Primary and

Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR

2018 ICD-O-3 Updates in Table Format with Annotation for Reference

Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS

Protocol for the Examination of Biopsy Specimens From Patients With Invasive Carcinoma of the Breast

Breast pathology. 2nd Department of Pathology Semmelweis University

INDEX. in this web service Cambridge University Press

Differential Diagnosis of Oral Masses. Palatal Lesions

Breast Pathology. Breast Development

Enterprise Interest None

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast

Chapter 13 Cancer of the Female Breast

CLINICAL SIGNIFICANCE OF BENIGN EPITHELIAL CHANGES

Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of

04/10/2018. Intraductal Papillary Neoplasms Of Breast INTRADUCTAL PAPILLOMA

A712(19)- Test slide, Breast cancer tissues with corresponding normal tissues

ICD-O Morphology code. R=Rare Tier Tumour ICD-O Topography code C30.0, C31

University Journal of Pre and Para Clinical Sciences

2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:

Multiple Primary and Histology Site Specific Coding Rules BREAST. FLORIDA CANCER DATA SYSTEM MPH Breast Site Specific Coding Rules

Histological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis

Surgical Pathology Issues of Practical Importance

2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING

Appendix 4: WHO Classification of Tumours of the pancreas 17

The European Commission s science and knowledge service. Joint Research Centre

ACRIN 6666 Therapeutic Surgery Form

DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #

Breast Cancer 100: Overview of Breast Cancer in Native Americans

Papillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.

BREAST PATHOLOGY. Fibrocystic Changes

Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine

Papillary Lesions of the breast

Terminal duct lobular unit (TDLU). A, Diagrammatic representation of this structure. ETD = Extralobular terminal duct; ITD = intralobular terminal

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

List of Available TMAs in the PRN

My Personalized Breast Cancer Worksheet

Treatment options for the precancerous Atypical Breast lesions. Prof. YOUNG-JIN SUH The Catholic University of Korea

Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted

Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami

Classification System

Instructions for Completing Breast Cancer Surgery Outcomes (BRCASO) Data Form

Benign Mimics of Malignancy in Breast Pathology

A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues

Interpretation of Breast Pathology in the Era of Minimally Invasive Procedures

Histopathological Spectrum of Neoplastic and Non-neoplastic Breast Lesions: A Two Years Study

Abid Irshad, MD Director Breast Imaging. Medical University of South Carolina Charleston

HISTOMORPHOLOGICAL SPECTRUM OF BREAST LESIONS

Molecular classification of breast cancer implications for pathologists. Sarah E Pinder

Breast Health Programme at S.G.P.G.I.

Breast. Presentation Outline

Breast. FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.

Using the 7 th edition American Joint Commission on Cancer (AJCC) Cancer Staging Manual to Determine Esophageal Cancer Staging in SEER-Medicare Data

Enrollment Form: Pancreas

Ductal Carcinoma in Situ. Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA

ANNUAL CANCER REGISTRY REPORT-2017, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN

Slide seminar. Asist. Prof. Jože Pižem, MD, PhD Institute of Pathology Medical Faculty, University of Ljubljana

Farid Moinfar Essentials of Diagnostic Breast Pathology

BREAST PATHOLOGY MCQS

Rare types of breast carcinoma

Diseases of the breast (1 of 2)

Enterprise Interest None

EQA Circulation 43 Educational Cases

FINALIZED SEER SINQ QUESTIONS

Your Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:

Non-mass Enhancement on Breast MRI. Aditi A. Desai, MD Margaret Ann Mays, MD

ANNUAL CANCER REGISTRY REPORT-2015

FINALIZED SEER SINQ S MAY 2012

ANNUAL CANCER REGISTRY REPORT-2016, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN

Quiz. b. 4 High grade c. 9 Unknown

Update on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.

Rare Breast Cancers and Male Breast Cancer

6/3/2010. Outline of Talk. Lobular Breast Cancer: Definition of lobular differentiation. Common Problems in Diagnosing LCIS in Core Biopsies

Pancreatic Cytopathology: The Solid Neoplasms

Malignant Breast disorders

Low-grade Adenosquamous Carcinoma Coexisting with Sclerosing Adenosis of the Breast: A Case Report

FCDS 2013 EDUCATION WEBCAST SERIES: BREAST CANCER

Ground Glass Opacities

Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction

Synchronous squamous cell carcinoma of the breast. and invasive lobular carcinoma

Salivary Glands 3/7/2017

FINALIZED SEER SINQ S NOVEMBER 2011

Breast Cancer. Dr. Andres Wiernik 2017

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

Icd 10 code for breast cancer stage 2

Update in Salivary Gland Pathology. Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016

Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק

Clinicopathological comparison of triple negative breast cancers with non triple negative breast cancers in a hospital in North India

TOTALS 30. Preliminary analysis of NNDEQA 004 (May 2013 TSL workshops) 1) 70 year old female with focal irregularity in the right breast.

FINALIZED SEER SINQ QUESTIONS April July, 2017

Breast Cancer. Dr Rodney Itaki Anatomical Pathology Discipline Division of Pathology

Transcription:

BMaP-3 Cancer Database Aggregate Data File Contents BMaP-3 Cancer Database... 1 Aggregate Data File... 1 Frequency Tables... 2 Institution... 2 Year_First_Contact... 2 Primary_Site... 3 Sex... 3 Race... 4 Spanish_Hispanic... 4 Histology_Behavior... 5 Year_Surgery... 10 Surg_Primary_Site... 11 Systemic_Surgery_Seq... 13 Radiation_Surgery_Seq... 14 Tumor_Marker_1_ERA... 14 Tumor_Marker_2_PRA... 15 Her2Neu... 15 Path_TNM_Group_Stage... 16 Site_Specific_Factor_16... 17 Site_Specific_Factor_16_kf... 18 Race_3... 18 TMA... 18 Changes_Made_From_Path_Reports... 19 Descriptives... 19 Age_at_Diagnosis... 19 1

Frequency Tables Institution EMO 708 8.8 8.8 8.8 MCC 6200 76.6 76.6 85.4 TUL 313 3.9 3.9 89.3 UAB 718 8.9 8.9 98.1 UMI 151 1.9 1.9 100.0 Year_First_Contact 2000 2.0.0.0 2001 740 9.1 9.1 9.2 2002 679 8.4 8.4 17.6 2003 761 9.4 9.4 27.0 2004 783 9.7 9.7 36.7 2005 765 9.5 9.5 46.1 2006 688 8.5 8.5 54.6 2007 706 8.7 8.7 63.3 2008 719 8.9 8.9 72.2 2009 745 9.2 9.2 81.4 2010 770 9.5 9.5 91.0 2011 732 9.0 9.0 100.0 2

Primary_Site C500 (BREAST NIPPLE) 59.7.7.7 C501 (BREAST CENTRAL) 390 4.8 4.8 5.6 C502 (BREAST UIQ) 755 9.3 9.3 14.9 C503 (BREAST LIQ) 471 5.8 5.8 20.7 C504 (BREAST UOQ) 2646 32.7 32.7 53.4 C505 (BREAST LOQ) 479 5.9 5.9 59.3 C506 (BREAST TAIL) 37.5.5 59.8 C508 Breast, lower 8.1.1 59.9 C508 Breast, midline of 37.5.5 60.3 C508 Breast, outer 9.1.1 60.5 C508 Breast, upper 6.1.1 60.5 C508 (BREAST OVERLAPPING LESION) 2224 27.5 27.5 88.0 C508 Breast, inner 5.1.1 88.1 C509 (BREAST NOS) 964 11.9 11.9 100.0 Sex FEMALE 8030 99.3 99.3 99.3 MALE 59.7.7 100.0 Not stated in patient record 1.0.0 100.0 3

Race AM INDIAN 2.0.0.0 ASIAN INDIAN 1.0.0.0 ASIAN OTHER/NOS 1.0.0.0 BLACK 2012 24.9 24.9 24.9 FILIPINO 2.0.0 24.9 OTHER 80 1.0 1.0 25.9 PACIFIC ISLANDER NOS 3.0.0 26.0 UNKNOWN 82 1.0 1.0 27.0 VIETNAMESE 3.0.0 27.0 WHITE 5904 73.0 73.0 100.0 Spanish_Hispanic CUBAN(3) 43.5.5.5 DOMINICAN REPUBLIC(8) 7.1.1.6 MEXICAN(1) 24.3.3.9 NON-SPANISH(0) 7370 91.1 91.1 92.0 OTHER SPANISH ORIGIN(5) 9.1.1 92.1 PUERTO RICAN(2) 59.7.7 92.9 SOUTH/CENTRAL 66.8.8 93.7 AMERICAN(4) SPANISH NOS(6) 368 4.5 4.5 98.2 SPANISH SURNAME ONLY(7) 2.0.0 98.2 UNKNOWN(9) 142 1.8 1.8 100.0 4

Histology_Behavior 5.1.1.1 80003 (NEOPLASM MALIGNANT) 80102 (CARCINOMA IN SITU NOS) 3.0.0.1 3.0.0.1 80103 ( 22.3.3.4 80123 (LARGE CELL 80223 (PLEOMORPHIC 80323 (SPINDLE CELL 80333 (SARCOMATOID 80413 (SMALL CELL 80502 (PAPILLARY CARCINOMA IN SITU) 80503 (PAPILLARY 80703 (SQUAMOUS CELL CARCINOMA, NOS) 80713 (SQUAMOUS CELL CARCINOMA KERATINIZING NOS) 80743 (SQUAMOUS CELL CARCINOMA SPINDLE CELL) 81403 (ADENOCARCINOMA, NOS) 82003 (ADENOID CYSTIC 82012 (CRIBRIFORM CARCINOMA IN SITU) 1.0.0.4 1.0.0.4 1.0.0.4 1.0.0.5 1.0.0.5 5.1.1.5 15.2.2.7 6.1.1.8 1.0.0.8 1.0.0.8 23.3.3 1.1 8.1.1 1.2 107 1.3 1.3 2.5 5

82013 (CRIBRIFORM 82113 (TUBULAR ADENO 82302 (DUCTAL CARCINOMA IN SITU SOLID TYPE) 82303 (SOLID CARCINOMA NOS) 82463 (NEUROENDOCRINE 82553 (ADENOCARCINOMA WITH MIXED SUBTYPES) 82603 (PAPILLARY ADENO 83103 (CLEAR CELL ADENO 83233 (MIXED CELL ADENO 84012 (APOCRINE ADENOCA INSITU) 84013 (APOCRINE ADENO 84803 (MUCINOUS ADENO 84903 (SIGNET RING CELL 85002 (INTRADUCTAL CARCINOMA NONINFILTRATING NOS) 85003 (INFILTRATING DUCT 85012 (COMEDOCARCINOMA NONINFILTRATING) 21.3.3 2.8 101 1.2 1.2 4.0 77 1.0 1.0 5.0 4.0.0 5.0 1.0.0 5.0 7.1.1 5.1 2.0.0 5.2 1.0.0 5.2 6.1.1 5.2 5.1.1 5.3 26.3.3 5.6 99 1.2 1.2 6.8 1.0.0 6.9 572 7.1 7.1 13.9 4453 55.0 55.0 69.0 76.9.9 69.9 6

85013 (COMEDOCARCINOMA NOS) 85023 (SECRETORY CARCINOMA OF BREAST) 85032 (NONINFILTRATING INTRADUCTAL PAPILLARY ADENO 85033 (INTRADUCTAL PAPILLARY ADENOCARCINOMA WITH INVASION) 85042 (NONINFILTRATING INTRACYSTIC 85043 (INTRACYSTIC 85072 (INTRADUCTAL MICROPAPILLARY 85073 (MICROPAPILLARY CA INVASIVE) 85103 (MEDULLARY 85133 (ATYPICAL MEDULLARY 85202 (LOBULAR CARCINOMA IN SITU NOS) 85203 (LOBULAR 85213 (INFILTRATING DUCTULAR 85222 (INTRADUCTAL CARCINOMA AND LOBULAR CARCINOMA IN SITU) 10.1.1 70.0 2.0.0 70.1 40.5.5 70.6 22.3.3 70.8 4.0.0 70.9 7.1.1 71.0 53.7.7 71.6 27.3.3 72.0 56.7.7 72.6 1.0.0 72.7 100 1.2 1.2 73.9 522 6.5 6.5 80.3 12.1.1 80.5 44.5.5 81.0 7

85223 (INFILTRATING DUCT AND LOBULAR 85232 (DCIS & MIXED W/OTHER IN SITU) 85233 (INFILTRATING DUCT MIXED WITH OTHER TYPES OF 85243 (INFILTRATING LOBULAR MIXED WITH OTHER TYPES OF 85303 (INFLAMMATORY 85402 (PAGET DISEASE IN SITU) 85403 (Paget disease, mammary) 85413 (PAGET DISEASE AND INFILTRATING DUCT CARCINOMA OF BREAST) 85432 (PAGET DISEASE AND INTRADUCTAL CARCINOMA IN SITU) 85433 (PAGET DISEASE AND INTRADUCTAL CARCINOMA OF BREAST) 85603 (ADENOSQUAMOUS 85723 (ADENOCARCINOMA WITH SPINDLE CELL METAPLASIA) 85743 (ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION) 534 6.6 6.6 87.6 292 3.6 3.6 91.2 467 5.8 5.8 97.0 41.5.5 97.5 30.4.4 97.9 3.0.0 97.9 2.0.0 98.0 19.2.2 98.2 11.1.1 98.3 13.2.2 98.5 2.0.0 98.5 2.0.0 98.5 2.0.0 98.6 8

85753 (METAPLASTIC 30.4.4 98.9 88003 (SARCOMA NOS) 3.0.0 99.0 88013 (SPINDLE CELL SARCOMA) 88023 (GIANT CELL SARCOMA (EXCEPT OF BONE)) 88943 (ANGIOMYOSARCOMA) 89353 (Stromal sarcoma, NOS) 89803 (CARCINOSARCOMA NOS) 89823 (MALIGNANT MYOEPITHELIOMA) 90203 (PHYLLODES TUMOR MALIGNANT) 91203 (HEMANGIOSARCOMA) 91803 (OSTEOSARCOMA NOS) 95803 (GRANULAR CELL TUMOR MALIGNANT) 3.0.0 99.0 1.0.0 99.0 1.0.0 99.0 1.0.0 99.0 1.0.0 99.1 1.0.0 99.1 15.2.2 99.3 19.2.2 99.5 1.0.0 99.5 1.0.0 99.5 NA 39.5.5 100.0 9

Year_Surgery 0 80 1.0 1.0 1.0 1996 1.0.0 1.0 1997 1.0.0 1.0 2000 19.2.2 1.2 2001 690 8.5 8.5 9.8 2002 688 8.5 8.5 18.3 2003 736 9.1 9.1 27.4 2004 778 9.6 9.6 37.0 2005 732 9.0 9.0 46.0 2006 685 8.5 8.5 54.5 2007 689 8.5 8.5 63.0 2008 706 8.7 8.7 71.8 2009 720 8.9 8.9 80.7 2010 766 9.5 9.5 90.1 2011 721 8.9 8.9 99.0 2012 78 1.0 1.0 100.0 10

Surg_Primary_Site CODE 41 + COMBINED 38.5.5.5 CODE 41 + IMPLANT 159 2.0 2.0 2.4 CODE 41 + RECONSTRUCT NOS 37.5.5 2.9 CODE 41 + TISSUE 93 1.1 1.1 4.0 CODE 42 + COMBINED 26.3.3 4.4 CODE 42 + IMPLANT 216 2.7 2.7 7.0 CODE 42 + RECONSTRUCT NOS 17.2.2 7.2 CODE 42 + TISSUE 72.9.9 8.1 CODE 51 + IMPLANT 35.4.4 8.6 CODE 51 + RECONSTRUCT NOS 18.2.2 8.8 CODE 51 + TISSUE 26.3.3 9.1 Code 51 w/reconstruction - Combined (tissue and implant) 6.1.1 9.2 CODE 52 + COMBINED 7.1.1 9.3 CODE 52 + IMPLANT 27.3.3 9.6 CODE 52 + RECONSTRUT NOS 2.0.0 9.6 CODE 52 + TISSUE 16.2.2 9.8 CODE 62 + RECONSTRUCT NOS Code 62 w/reconstruction - Tissue EXT RAD MAST W/O UNINV Extended radical mastectomy 1.0.0 9.8 2.0.0 9.9 2.0.0 9.9 3.0.0 9.9 Local tumor excision, NOS 1.0.0 9.9 LUMPECTOMY OR EXC BX 4179 51.7 51.7 61.6 MASTECTOMY NOS 7.1.1 61.7 11

MOD RAD MAST W UNINV BRST MOD RAD MAST W/O UNINV 135 1.7 1.7 63.3 538 6.7 6.7 70.0 MOD RAD MASTECTOMY 158 2.0 2.0 72.0 NONE; AUTOPSY ONLY 305 3.8 3.8 75.7 PART MAST W NIPPLE RESECT PART OR < MASTECTOMY NOS RAD MAST + RECONST NOS 45.6.6 76.3 308 3.8 3.8 80.1 2.0.0 80.1 RAD MAST + TISSUE 2.0.0 80.1 RAD MAST W/O UNINV BRST 7.1.1 80.2 RAD MASTECTOMY NOS 4.0.0 80.3 REEXC FOR GROSS OR MICRO SEGMENTAL MASTECTOMY SUBCUTANEOUS MASTECTOMY 257 3.2 3.2 83.4 304 3.8 3.8 87.2 24.3.3 87.5 SURGERY NOS 14.2.2 87.7 TOT SIMPLE MASTECTOMY NOS TOT/SIMP W UNINV BREAST TOT/SIMP W/O UNINV BREAST 156 1.9 1.9 89.6 205 2.5 2.5 92.1 635 7.8 7.8 100.0 UNKNOWN; DC ONLY 1.0.0 100.0 12

Systemic_Surgery_Seq INTRAOP SYSTEMIC PLUS 1.0.0.0 NA 355 4.4 4.4 4.4 NO SYSTEMIC RX OR NO SURG 1237 15.3 15.3 19.7 NONE 2493 30.8 30.8 50.5 Sequence unknown, but both surgery and systemic therapy given SYSTEMIC AFTER SURGERY SYSTEMIC BEF & AFTER SURG SYSTEMIC BEFORE SURGERY 178 2.2 2.2 52.7 3167 39.1 39.1 91.9 279 3.4 3.4 95.3 380 4.7 4.7 100.0 13

Radiation_Surgery_Seq Intraoperative Radiation 31.4.4.4 Intraoperative with bef/aft 2.0.0.4 NA 2340 28.9 28.9 29.3 No Documented Radiation 381 4.7 4.7 34.0 No Radiation And/Or Ca-Directed Surgery 861 10.6 10.6 44.7 NOT APPL 253 3.1 3.1 47.8 RAD BEF & AFT SURG 3.0.0 47.8 Radiation before Surgery 29.4.4 48.2 Radiation on Same day of Surgery 3.0.0 48.2 Sequence unknown 4.0.0 48.3 Surgery before Radiation 4183 51.7 51.7 100.0 Tumor_Marker_1_ERA BORDERLINE, UNDETERMINED 3.0.0.0 NEGATIVE/NORMAL 1544 19.1 19.1 19.1 NONE DONE 147 1.8 1.8 20.9 ORDERED, NO RESULTS 12.1.1 21.1 POSITIVE/ELEVATED 4649 57.5 57.5 78.6 UNKNOWN 1735 21.4 21.4 100.0 14

Tumor_Marker_2_PRA BORDERLINE, UNDETERMINED 9.1.1.1 NEGATIVE/NORMAL 2231 27.6 27.6 27.7 NONE DONE 151 1.9 1.9 29.6 ORDERED, NO RESULTS 12.1.1 29.7 POSITIVE/ELEVATED 3940 48.7 48.7 78.4 UNKNOWN 1747 21.6 21.6 100.0 Her2Neu BORDERLINE, EQUIVOCAL 26.3.3.3 NA 336 4.2 4.2 4.5 NEGATIVE/NORMAL 1004 12.4 12.4 16.9 NONE DONE 4421 54.6 54.6 71.5 NOT APPLICABLE 1306 16.1 16.1 87.7 Ordered but results not available PERFORMED, RESULTS UNK 1.0.0 87.7 4.0.0 87.7 POSITIVE/ELEVATED 206 2.5 2.5 90.3 UNKNOWN 786 9.7 9.7 100.0 15

Path_TNM_Group_Stage 35.4.4.4 0 1342 16.6 16.6 17.0 1 2514 31.1 31.1 48.1 1A 533 6.6 6.6 54.7 1B 25.3.3 55.0 2 37.5.5 55.5 2A 1535 19.0 19.0 74.4 2B 730 9.0 9.0 83.4 3 14.2.2 83.6 3A 424 5.2 5.2 88.9 3B 105 1.3 1.3 90.2 3C 196 2.4 2.4 92.6 4 39.5.5 93.1 88 33.4.4 93.5 99 528 6.5 6.5 100.0 16

Site_Specific_Factor_16 ER NEGATIVE; PR NEGATIVE; HER2 NEGATIVE (Triple Negative) ER NEGATIVE; PR NEGATIVE; HER2 POSITIVE ER NEGATIVE; PR POSITIVE; HER2 NEGATIVE ER NEGATIVE; PR POSITIVE; HER2 POSITIVE ER POSITIVE; PR NEGATIVE; HER2 NEGATIVE ER POSITIVE; PR NEGATIVE; HER2 POSITIVE ER POSITIVE; PR POSITIVE; HER2 NEGATIVE ER POSITIVE; PR POSITIVE; HER2 POSITIVE 323 4.0 4.0 4.0 52.6.6 4.6 16.2.2 4.8 1.0.0 4.8 94 1.2 1.2 6.0 32.4.4 6.4 774 9.6 9.6 16.0 89 1.1 1.1 17.1 NA 1676 20.7 20.7 37.8 NOT APPLICABLE 4904 60.6 60.6 98.4 UNKNOWN 129 1.6 1.6 100.0 17

Site_Specific_Factor_16_kf HR+/Her2-1240 15.3 15.3 15.3 HR+/Her2+ 192 2.4 2.4 17.7 NA 6115 75.6 75.6 93.3 PR-/ER-/Her2-445 5.5 5.5 98.8 PR-/ER-/Her2+ 98 1.2 1.2 100.0 Race_3 AA 1948 24.1 24.1 24.1 Hisp 555 6.9 6.9 30.9 NA 211 2.6 2.6 33.5 White 5376 66.5 66.5 100.0 TMA No 7831 96.8 96.8 96.8 Yes 259 3.2 3.2 100.0 18

Changes_Made_From_Path_Reports No 8081 99.9 99.9 99.9 Yes 9.1.1 100.0 Descriptives Age_at_Diagnosis Descriptive Statistics N Minimum Maximum Mean Std. Deviation Age_at_Diagnosis 8090 18 96 57.16 12.810 N (listwise) 8090 19